Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KPTI
  • CUSIP: N/A
  • Web: www.karyopharm.com
Capitalization:
  • Market Cap: $421.71 million
  • Outstanding Shares: 47,118,000
Average Prices:
  • 50 Day Moving Avg: $10.08
  • 200 Day Moving Avg: $10.25
  • 52 Week Range: $6.27 - $14.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.87
  • P/E Growth: -0.12
Sales & Book Value:
  • Annual Revenue: $222,000.00
  • Price / Sales: 1,899.58
  • Book Value: $3.30 per share
  • Price / Book: 2.71
Profitability:
  • EBIDTA: ($112,940,000.00)
  • Return on Equity: -64.20%
  • Return on Assets: -58.62%
Debt:
  • Current Ratio: 8.71%
  • Quick Ratio: 8.71%
Misc:
  • Average Volume: 361,587 shs.
  • Beta: 4.49
  • Short Ratio: 5.85
 

Frequently Asked Questions for Karyopharm Therapeutics (NASDAQ:KPTI)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.71) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.04. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.02 million. During the same period last year, the firm posted ($0.75) earnings per share. View Karyopharm Therapeutics' Earnings History.

Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2017?

8 analysts have issued 12-month price targets for Karyopharm Therapeutics' shares. Their forecasts range from $7.55 to $20.00. On average, they expect Karyopharm Therapeutics' share price to reach $15.44 in the next twelve months. View Analyst Ratings for Karyopharm Therapeutics.

What are analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
  • 2. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (3/21/2017)
  • 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)

Are investors shorting Karyopharm Therapeutics?

Karyopharm Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,610,965 shares, an increase of 5.1% from the March 31st total of 2,483,391 shares. Based on an average daily volume of 295,943 shares, the days-to-cover ratio is presently 8.8 days.

Who are some of Karyopharm Therapeutics' key competitors?

Who owns Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (13.80%), FMR LLC (10.32%), Palo Alto Investors LLC (7.23%), Vanguard Group Inc. (2.95%), Tekla Capital Management LLC (1.44%) and JPMorgan Chase & Co. (1.24%). Company insiders that own Karyopharm Therapeutics stock include Ltd Chione, Mansoor Raza Mirza and Ran Frenkel. View Institutional Ownership Trends for Karyopharm Therapeutics.

Who sold Karyopharm Therapeutics stock? Who is selling Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Candriam Luxembourg S.C.A., Morgan Stanley, Goldman Sachs Group Inc., ProShare Advisors LLC, Credit Suisse AG, United Services Automobile Association and Alliancebernstein L.P.. Company insiders that have sold Karyopharm Therapeutics stock in the last year include Ltd Chione and Ran Frenkel. View Insider Buying and Selling for Karyopharm Therapeutics.

Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Iguana Healthcare Management LLC, EAM Investors LLC, Palo Alto Investors LLC, Vanguard Group Inc., JPMorgan Chase & Co., Tekla Capital Management LLC and Ameriprise Financial Inc.. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy Karyopharm Therapeutics stock?

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Karyopharm Therapeutics stock cost?

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $8.95.

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $15.44 (72.56% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/15/2017Cantor FitzgeraldReiterated RatingOverweight$18.00LowView Rating Details
4/7/2017Jefferies Group LLCReiterated RatingBuy$17.00HighView Rating Details
4/6/2017Robert W. BairdReiterated RatingOutperform$15.00LowView Rating Details
4/5/2017WedbushReiterated RatingOutperform$14.00MediumView Rating Details
3/17/2017HC WainwrightReiterated RatingBuy$14.00MediumView Rating Details
3/13/2017Canaccord GenuityReiterated RatingBuy$20.00LowView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperform$18.00N/AView Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55N/AView Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$13.00N/AView Rating Details
3/15/2016Bank of America CorpDowngradeNeutral -> Underperform$26.00 -> $11.00N/AView Rating Details
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00N/AView Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00N/AView Rating Details
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Earnings History by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.67)($0.71)$0.02 million$0.07 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.65)($0.65)$0.18 million$0.05 millionViewN/AView Earnings Details
11/7/2016Q316($0.81)($0.69)$0.18 million$0.05 millionViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)$0.18 million$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)$0.30 millionViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)$0.30 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)$0.30 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)$0.30 million$0.15 millionViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)$0.30 millionViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)$0.11 million$0.02 millionViewListenView Earnings Details
11/10/2014Q314($0.53)($0.61)$0.20 million$0.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.51)($0.55)$0.20 million$0.02 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.45)($0.46)$0.25 million$0.17 millionViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
2017 EPS Consensus Estimate: ($2.54)
2018 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.66)($0.62)($0.63)
Q2 20173($0.64)($0.60)($0.62)
Q3 20172($0.65)($0.62)($0.64)
Q4 20172($0.66)($0.64)($0.65)
Q1 20181($0.59)($0.59)($0.59)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Ownership Percentage: 14.79%
Institutional Ownership Percentage: 56.97%
Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.54View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Karyopharm Therapeutics (NASDAQ:KPTI)
Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
Source:
DateHeadline
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Downgraded by ValuEngine
www.americanbankingnews.com - May 25 at 3:37 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Phase 2b SADAL Data Evaluating Selinexor in DLBCL Selected for Oral Presentation ... - StreetInsider.com
www.streetinsider.com - May 19 at 10:57 PM
nasdaq.com logoPhase 2b SADAL Data Also Selected for Poster Presentation at ICML 2017
www.nasdaq.com - May 18 at 8:58 AM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Phase 2b SADAL Data Evaluating Selinexor in DLBCL Selected for Oral Presentation at EHA
www.streetinsider.com - May 18 at 8:58 AM
finance.yahoo.com logoKaryopharm’s Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
finance.yahoo.com - May 18 at 8:58 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc Forecasted to Earn FY2017 Earnings of ($2.54) Per Share (KPTI)
www.americanbankingnews.com - May 17 at 8:50 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 15 at 11:56 AM
americanbankingnews.com logoCantor Fitzgerald Initiates Coverage on Karyopharm Therapeutics Inc (KPTI)
www.americanbankingnews.com - May 15 at 11:04 AM
americanbankingnews.com logoZacks: Analysts Anticipate Karyopharm Therapeutics Inc (KPTI) Will Announce Quarterly Sales of $50,000.00
www.americanbankingnews.com - May 12 at 12:02 PM
americanbankingnews.com logo Brokerages Expect Karyopharm Therapeutics Inc (KPTI) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - May 10 at 10:16 PM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Announces Earnings Results
www.americanbankingnews.com - May 9 at 12:16 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 8 at 11:53 PM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 8 at 10:26 PM
americanbankingnews.com logoWedbush Comments on Karyopharm Therapeutics Inc's Q1 2018 Earnings (KPTI)
www.americanbankingnews.com - May 8 at 11:18 AM
americanbankingnews.com logoKaryopharm Therapeutics (KPTI) Receives Daily Coverage Optimism Score of 0.25
www.americanbankingnews.com - May 6 at 12:52 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Short Interest Up 5.1% in April
www.americanbankingnews.com - May 5 at 12:24 PM
finance.yahoo.com logoEdited Transcript of KPTI earnings conference call or presentation 4-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 11:24 PM
finance.yahoo.com logoKaryopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
finance.yahoo.com - May 4 at 6:22 PM
finance.yahoo.com logoInvestor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 6:22 PM
nasdaq.com logoBPMX Craters, KPTI Surges On Deal With Anivive, PFE Seeks New Use For Old Drug - Nasdaq
www.nasdaq.com - May 4 at 12:02 PM
marketbeat.com logoKaryopharm Therapeutics posts 1Q loss
marketbeat.com - May 4 at 9:12 AM
streetinsider.com logoKaryopharm Therapeutics (KPTI), Anivive Lifesciences Enter Global License Agreement for Verdinexor for Animal Health Applications
www.streetinsider.com - May 3 at 10:20 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI), Anivive Lifesciences Enter Global License Agreement for Verdinexor for Animal ... - StreetInsider.com
www.streetinsider.com - May 3 at 5:19 PM
finance.yahoo.com logoKaryopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
finance.yahoo.com - May 3 at 5:19 PM
americanbankingnews.com logoKaryopharm Therapeutics (KPTI) Receives Coverage Optimism Rating of 0.31
www.americanbankingnews.com - May 1 at 5:04 PM
americanbankingnews.com logoKaryopharm Therapeutics (KPTI) Receiving Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 27 at 10:32 PM
finance.yahoo.com logoKaryopharm Therapeutics, Inc. – Value Analysis (NASDAQ:KPTI) : April 27, 2017
finance.yahoo.com - April 27 at 6:47 PM
feeds.benzinga.com logoKaryopharm to Report First Quarter 2017 Financial Results on May 4, 2017
feeds.benzinga.com - April 27 at 8:08 AM
streetinsider.com logoKaryopharm Therapeutics (KPTI) to Offer $40M in Common Stock - StreetInsider.com
www.streetinsider.com - April 26 at 7:07 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Prices 3.9M Common Stock Offering at $10.25/Share - StreetInsider.com
www.streetinsider.com - April 26 at 7:07 PM
finance.yahoo.com logoKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : April 26, 2017
finance.yahoo.com - April 26 at 7:07 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Prices 3.9M Common Stock Offering at $10.25/Share
www.streetinsider.com - April 25 at 5:37 PM
finance.yahoo.com logoNewton cancer biotech Karyopharm plans to raise $40M in stock sale
finance.yahoo.com - April 25 at 5:37 PM
finance.yahoo.com logoKaryopharm Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 25 at 5:37 PM
globenewswire.com logoKaryopharm Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - April 25 at 5:43 AM
finance.yahoo.com logoKaryopharm Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 25 at 5:43 AM
americanbankingnews.com logoKaryopharm Therapeutics (KPTI) Earns Daily News Impact Rating of 0.17
www.americanbankingnews.com - April 24 at 9:36 PM
thestreet.com logoCommit To Purchase Karyopharm Therapeutics At $7.50, Earn 15% Annualized Using Options - TheStreet.com
www.thestreet.com - April 22 at 6:28 AM
finance.yahoo.com logoSix Stocks Spiking Up With Huge Volume
finance.yahoo.com - April 19 at 11:18 PM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 11:40 AM
americanbankingnews.com logoKaryopharm Therapeutics (KPTI) Earning Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 16 at 10:16 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Likely to Effect Karyopharm Therapeutics (KPTI) Share Price
www.americanbankingnews.com - April 13 at 7:21 PM
finance.yahoo.com logoKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : April 12, 2017
finance.yahoo.com - April 12 at 8:37 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - April 7 at 5:50 PM
finance.yahoo.com logoKaryopharm and Medidata Expand Clinical Trial Partnership
finance.yahoo.com - April 7 at 10:42 AM
finance.yahoo.com logoKaryopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 7 at 10:42 AM
finance.yahoo.com logoWhy Karyopharm Therapeutics Inc Stock Gained 16.4% in March
finance.yahoo.com - April 7 at 10:42 AM
americanbankingnews.com logoKaryopharm Therapeutics Inc (KPTI) Earns "Outperform" Rating from Robert W. Baird
www.americanbankingnews.com - April 6 at 9:31 AM
americanbankingnews.com logoWedbush Reiterates "Outperform" Rating for Karyopharm Therapeutics Inc (KPTI)
www.americanbankingnews.com - April 5 at 1:33 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) CFO Steps Down to Pursue Other Opportunities
www.streetinsider.com - April 4 at 7:08 AM

Social

Chart

Karyopharm Therapeutics (KPTI) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff